ComplyRx
Built by ComplyRx

Compare clinical trial pipelines, export for presentations

dupilumab (16) vs lebrikizumab (16)15 active2012–2030
dupilumablebrikizumab
Key
Actual date
Anticipated
Forecast to primary completion
RecruitingActive, not recruitingEnrolling by invitationNot yet recruitingCompletedTerminated
'12
'14
'16
'18
'20
'22
'24
'26
'28
'30
dupilumab
Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic DermatitisP2
Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)P3
A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically AdvisableP3
Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic DermatitisP4
Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)P3
Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic DermatitisP3
GRADUATEP2
ADaptP3
DISCOVERP4
Dupilumab Effects Against Aeroallergen ChallengeP2
TORNADOP4
PEDALP2
DeTECTSP2
Tapering of Biologics in Chronic Rhinosinusitis With Nasal PolypsP4
A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic DermatitisP2
A Phase III Study of GS101 Injection to Dupixent®P3
lebrikizumab
A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller MedicationP3
A Study of Lebrikizumab in Participants With Uncontrolled Asthma on Inhaled Corticosteroids and a Second Controller MedicationP3
A Study of Lebrikizumab in Adolescent Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller MedicationP3
A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)P2
A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate AsthmaP3
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)P2
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)P3
ADvocate2P3
ADjoinP3
ADvantageP3
ADorable-1P3
ADorable-2P3
A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic DermatitisP3
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)P3
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)P3
ADhope 2P3

Upcoming readouts

10 ahead · 2 drugs

Select a trial to load its full ClinicalTrials.gov record.

Trial Pipeline · How it works

Search, compare, export.

Three steps from drug name to a presentation-ready pipeline view, with live trial data, side by side.

  1. 01 · SEARCH

    Search drugs

    Type a drug name and see the phase 2-4 trials from ClinicalTrials.gov.

  2. 02 · COMPARE

    Compare timelines

    See start dates, primary completions, and status on one timeline, up to five drugs at once.

  3. 03 · EXPORT

    Export for your deck

    Download a branded PNG or PDF. Share the URL. Every comparison state is linkable.

FAQ

Where does the data come from?
All trial data is sourced from ClinicalTrials.gov (CTGov). Results are cached for up to 6 hours so repeat loads stay fast.
Is this free?
Yes. Compare up to five drugs and export PNG or PDF at no cost. Export requires a one-time email to join the ComplyRx waitlist.
What is ComplyRx?
ComplyRx is an all-in-one marketing/competitive intelligence platform for organisations and individuals that work in healthcare, life sciences, and the pharmaceutical industry.
Join the waitlist

Be the first to access ComplyRx

We'll let you know as soon as your spot opens to use ComplyRx.

By joining, you agree to our Privacy Policy.